Infectious Diseases Unit, L.C. Fleming Hospital, Saint Martin, French West Indies.
Antimicrob Agents Chemother. 2013 Dec;57(12):6393-4. doi: 10.1128/AAC.01349-13. Epub 2013 Sep 30.
We describe the pharmacokinetics of raltegravir of a preterm newborn after short-course treatment of the mother tested HIV + the day of delivery. At age 1 month, the circulating concentration of raltegravir in the newborn was 29 ng/ml (the IC95 of RAL against HIV-1 is 15 ng/ml). Raltegravir should therefore be considered a potential transplacental postexposure prophylaxis for HIV-1 and an alternative to the use of boosted lopinavir in this context.
我们描述了一例 HIV 阳性母亲于分娩当天接受短程治疗后，其早产儿的拉替拉韦药代动力学。1 月龄时，新生儿循环中的拉替拉韦浓度为 29ng/ml（拉替拉韦抗 HIV-1 的 IC95 为 15ng/ml）。因此，拉替拉韦应被视为 HIV-1 潜在的胎盘暴露后预防药物，可替代该背景下使用洛匹那韦利托那韦。
